Protocol to assess the antitumor efficacy of an immunotherapeutic peptide in syngeneic orthotopic glioma mouse models

STAR Protoc. 2023 Mar 17;4(1):102049. doi: 10.1016/j.xpro.2023.102049. Epub 2023 Jan 19.

Abstract

Understanding the glioblastoma (GBM) immune microenvironment and development of clinical treatment drugs rely on suitable preclinical GBM models. Here, we present a protocol to establish syngeneic orthotopic glioma mouse models. We also describe the steps to intracranially deliver immunotherapeutic peptides and monitor the treatment response. Finally, we show how to assess the tumor immune microenvironment with treatment outcomes. For complete details on the use and execution of this protocol, please refer to Chen et al. (2021).1.

Keywords: Cancer; Health Sciences; Model Organisms; Neuroscience.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Glioblastoma* / pathology
  • Glioma* / drug therapy
  • Glioma* / pathology
  • Immunotherapy
  • Mice
  • Tumor Microenvironment